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Abstract To determine if lysophosphatidylcholine (lysoPC) is
able to induce proin£ammatory changes in monocytes, its ability
to stimulate arachidonic acid (AA) release, a product of phos-
pholipase A2 (PLA2) activity, has been analyzed. LysoPC in-
creased AA release in THP-1 and Mono Mac6 cells in a time-
and concentration-dependent manner. The monocytes expressed
both secretory and cytosolic PLA2 enzymes and AA release was
strongly reduced by cellular pretreatment with di¡erent PLA2
inhibitors and by pertussis toxin, an inhibitor of Gi-protein ac-
tivation. This indicates that both cytosolic and secretory PLA2
enzymes regulate speci¢c lysoPC receptor-induced AA release,
suggesting lysoPC participation in monocyte proin£ammatory
activation.
+ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier B.V. All rights reserved.
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1. Introduction
Phospholipase A2 (PLA2) enzymes constitute a large family
of lipolytic enzymes (for review see [1]) that catalyze hydroly-
sis of the fatty acid ester at the sn-2 position of phospholipids.
This leads to production of lysophospholipids, including lyso-
phosphatidylcholine (lysoPC), and free fatty acids. When the
latter is arachidonic acid (AA), it is converted to potent proin-
£ammatory mediators, prostaglandins, thromboxanes, leuko-
trienes, and lipoxins, collectively known as eicosanoids [2].
Lysophospholipids and eicosanoid lipid hormones are regula-
tors of various physiologic processes and pathologic condi-
tions [3]. Group IV cytosolic PLA2 (cPLA2), regulated by
Ca2þ-dependent membrane translocation and phosphoryla-
tion, have a preference for AA in membrane phospholipids
and play an essential role in agonist-induced AA release [4].
Secretory PLA2s (sPLA2) of group IIa and group V are also
involved in AA release and subsequent eicosanoid production
during in£ammatory conditions [5].
LysoPC regulates a broad range of cellular processes such
as monocyte chemotaxis, gene transcription, and monocyte
proin£ammatory cytokine secretion (for review see [6]). In
human endothelial cells, extracellular lysoPC induces AA re-
lease through activation of cPLA2 [7]. It has been indicated
that lysoPC act through platelet-activating factor (PAF) re-
ceptor [8], however, G-protein-coupled receptors speci¢c for
lysoPC have been described [9,10].
Several lines of evidence have suggested that lysoPC may be
responsible for many of the cellular e¡ects of oxidized low
density lipoprotein (oxLDL) in intima during early atheroscle-
rosis development (for review see [11]). Group IIa sPLA2 is
present in human arteries [12], and can colocalize with LDL
on proteoglycans [13]. This association of the enzyme with
certain glucose aminoglycans increases the enzyme’s LDL-
modifying activity, rendering the LDL particle more pro-
atherogenic [13,14]. Moreover, recently we showed that min-
imally oxLDL is able to induce expression of group IIa sPLA2
in human macrophages [15], and that lipolytically modi¢ed
LDL by sPLA2 or SMase markedly increase monocyte AA
mobilization (submitted).
It is likely that sPLA2 may contribute to the pathogenesis
of atherosclerosis by modifying LDL and releasing proin£am-
matory lipid mediators, such as lysoPC, at places of LDL
retention in the arterial wall [14]. However, the biological
consequence of local lysoPC accumulation for monocytes is
uncertain. Our results suggest that lysoPC participates in
monocyte proin£ammatory activation due to speci¢c dose-
and time-dependent activation of AA release.
2. Materials and methods
2.1. Materials
Phorbol 12-myristate 13-acetate (PMA), fatty acid-free bovine se-
rum albumin (BSA), insulin, oxalacetic acid, pyruvic acid, proprano-
lol, pertussis toxin (PTX) and lysoPC (C16:0) were purchased from
Sigma Chemical co. (St. Louis, MO, USA). L-glutamine, penicillin,
streptomycin and non-essential amino acids were from Gibco BRL
(Life technologies, Grand Island, NY, USA). SB203347, was a gen-
erous gift from James Winkler, Smith Kline Beedam (Pharmaceuti-
cals, PA, USA). Methyl arachidonyl £uorophosphate (MAFP) and
bromoenol lactone (BEL) were from Cayman Chemical (USA).
2.2. Cell culture
Human monocytic THP-1 cells and Mono Mac6 cells were main-
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tained as described by the Global Bioresource Center ATCC and [16],
respectively. THP-1 cells were di¡erentiated with 160 nM PMA.
2.3. RNA extraction
Total cellular RNA was isolated by Trizol extraction in accordance
with the manufacturer’s instructions (Gibco BRL, Life Technologies
Inc., Grand Island, NY).
2.4. Reverse transcription-polymerase chain reaction (RT-PCR)
detection of di¡erent PLA2 isoforms
cDNA was synthesized from total RNA and cDNA templates were
used in PCR ampli¢cation with primers for di¡erent groups of human
PLA2s as previously described [15,17]. Two new primers were de-
signed [18,19]: group IId sPLA2 fwd 5P-GTTCCTCAGCATG-
GAGCTC-3P, rev 5P-TCCGAGACTATATTGGAGG-3P ; group VI
PLA2 fwd 5P-TGACAATTCTCAGGTGCTGC-3P, rev 5P-TCTTT-
CCAGGGAGAAGGGAT-3P. The conditions for the PCR reactions
were denaturation at 95‡C for 50 s, annealing at 58‡C for 50 s and
elongation at 72‡C for 40 s, repeated 20^45U. For group VI (Ca2þ-
independent PLA2, iPLA2) and X PLA2 the annealing temperature
was 65‡C. PCR products were electrophoresed as previously described
[17]. Fragment length after polymerization: group IIa sPLA2 : 247 bp,
group IId sPLA2 : 339 bp, group IV cPLA2 : 465 bp, group V sPLA2 :
381 bp, group VI iPLA2 : 727 bp, group X sPLA2 : 417 bp.
2.5. Measurement of [3H]AA and [14C]oleic acid (OA) release
THP-1 or Mono Mac6 cells were labelled with [3H]AA and [14C]OA
as previously described [20]. LysoPC was added to the cell cultures in
prescribed concentrations and time periods in RPMI 1640 medium
containing 1 mg ml31 BSA. PLA2 inhibitors were added at indicated
concentrations 60^120 min prior to stimulation, propranolol 30 min
prior to stimulation and PTX 3 h before stimulation.
2.6. 3-(4,5-Dimethylthiazol-2-yl)-2,5-difenyl tetrazolium bromide
(MTT) assay
LysoPC and di¡erent chemical inhibitors were tested for cytotox-
icity by MTT assay as previously described [21].
2.7. cPLA2 enzyme activity assay
THP-1 cells were seeded (2U106 cells per well) and starved (0,5%
fetal calf serum) 18 h before stimulation. Thereafter, cPLA2 enzyme
activity was measured as described previously [20].
2.8. Data presentation
The data were compared by Kruskal^Wallis test for random sam-
ples, and data with P6 0,05 were considered signi¢cant. The data are
shown as meansRS.D. Data in Fig. 1 are given as disintegrations per
minute (DPM), while data in Figs. 2 and 3 are given as percentage of
[3H]AA or [14C]OA release with respect to total cellular radioactivity
setting the control value to zero. Figs. 5 and 7 are shown as percent
activity compared to lysoPC-stimulated cells. Fig. 6 is shown as per-
cent cPLA2 activity relative to non-stimulated cells. Each set of ex-
periments was repeated three times.
3. Results
3.1. LysoPC stimulates [3H]AA release in THP-1 and Mono
Mac6 cells
In order to determine lysoPC-induced proin£ammatory ac-
tivation of monocytes, this activation was assessed as [3H]AA
release in THP-1 and Mono Mac6 cells. Compared to un-
treated cells, lysoPC gave an eight-fold increase in [3H]AA
release in THP-1 cells and a three-fold increase in Mono
Mac6 cells (Fig. 1). However, when THP-1 cells were di¡er-
entiated with PMA for 72 h and then stimulated with lysoPC
the [3H]AA release was similar to the release observed in
Mono Mac6 cells (data not shown). Hence, our results suggest
that lysoPC stimulates AA release in monocytes, and that the
magnitude of AA release is di¡erentiation dependent.
LysoPC elicited a dose-dependent increase of [3H]AA re-
lease (Fig. 2), as well as a time-dependent increase with a
maximum after 10 and 5 min in THP-1 and Mono Mac6,
respectively (Fig. 3). Measurement of [14C]OA release was
performed in parallel with [3H]AA release, and showed a sim-
ilar pattern to [3H]AA release, except that [14C]OA release
was approximately 2/3 of [3H]AA release (Figs. 2 and 3).
Cell viability was determined by MTT assay and both cell
lines were 100% viable for optimal concentrations (40 and
30 WM) for 1 h after lysoPC exposure (results not shown).
Based on these results, 10 min stimulation with 40 WM lysoPC
was applied for THP-1, while 5 min stimulation with 30 WM
lysoPC was used for Mono Mac6 cells in subsequent experi-
ments.
3.2. sPLA2, cPLA2 and group VI iPLA2 are expressed in
THP-1 and Mono Mac6 cells
RT-PCR analysis with primers for di¡erent forms of PLA2
enzymes was performed on total RNA extracted from THP-1
and Mono Mac6 cells. Transcripts were detected for group
IId, IVK, and VI PLA2 in undi¡erentiated THP-1 cells (Fig.
4, lane 2), and in Mono Mac6 cells (Fig. 4, lane 1). Transcript
for group V PLA2 was detected only in THP-1 (Fig. 4, lane 2).
Upon PMA di¡erentiation of THP-1 cells, transcripts for
group IId, IV and VI PLA2 were found to be constitutively
expressed (Fig. 4, lanes 3 and 4), while expression of group V
sPLA2 was down-regulated upon di¡erentiation (Fig. 4, lanes
3 and 4). Group IIa and group X sPLA2 were not detected in
any of the monocytic cell lines.
3.3. Both sPLA2 and cPLA2 enzymes regulate [3H]AA release
Several speci¢c PLA2 inhibitors were examined for their
ability to reduce agonist-induced fatty acid release. The active
site-directed sPLA2 inhibitor, SB203347 [22], strongly inhib-
ited lysoPC-stimulated [3H]AA release dose dependently in
both THP-1 and Mono Mac6 cell lines with a maximum of
80% and 90% inhibition, respectively (Fig. 5A,B). The sPLA2
enzymes have, in in vitro assays, not been shown to display
any acyl chain selectivity [23] and SB203347 equally reduced
both lysoPC-stimulated [3H]AA and [14C]OA release, con¢rm-
ing a role for the group IId and V sPLA2 in monocyte AA
release.
Using MAFP, a dual cPLA2/group VI iPLA2 inhibitor [24],
the lysoPC-stimulated [3H]AA release was also dose depen-
Fig. 1. LysoPC stimulates [3H]AA release in human monocytic cell
lines. THP-1 and Mono Mac6 cells prelabelled with [3H]AA or
[14C]OA, were treated with lysoPC (40 and 30 WM, respectively) for
15 min.
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dently inhibited (Fig. 5C,D) in both THP-1 and Mono Mac6
cells with a maximum of 90% and 98% inhibition, respec-
tively. BEL is a potent group VI iPLA2 inhibitor [25] and
manifests a 1000-fold selectivity for inhibition of group VI
iPLA2 versus cPLA2 in vitro. BEL partially inhibited lyso-
PC-induced [3H]AA release (Fig. 5E,F) in THP-1 and Mono
Mac6 cells. To exclude that BEL exerts its reduction in ly-
soPC-stimulated AA release by inhibiting phosphatidic acid
phosphohydrolase (PAP) [26], propranolol, a well established
PAP inhibitor [27] was employed. LysoPC-stimulated AA re-
lease was, indeed, found to be reduced in the presence of
propranolol (Fig. 5G), while dual inhibition with BEL and
propranolol showed no additive e¡ect (Fig. 5H). Therefore
the initial inhibition observed with the dual cPLA2/group VI
iPLA2 inhibitor MAFP is due to inactivation of the cPLA2
enzyme which was further evidenced by assay of cPLA2 en-
zyme activity (Fig. 6).
3.4. Involvement of G-proteins in lysoPC-stimulated AA release
The Gi-protein inhibitor PTX was used on prelabelled
THP-1 cells. PTX inhibited the lysoPC-induced [3H]AA re-
lease by a maximum of 50% (Fig. 7), suggesting that a Gi-
protein partly mediates the lysoPC response in THP-1 cells.
4. Discussion
It is known that lysoPC mediate AA release in endothelial
cells [7], and that a major pathway for AA release from ago-
nist-stimulated cells is via hydrolysis of phospholipids by
Fig. 3. LysoPC challenge of THP-1 and Mono Mac6 cells gives a
peak in [3H]AA and [14C]OA release after, respectively, 10 and
5 min. Prelabelled (A) THP-1 or (B) Mono Mac6 cells were treated
with (A) 40 or (B) 30 WM lysoPC for 0^120 min.
Fig. 4. RT-PCR detection of groups IId, IV, V, VI PLA2 in THP-1
cells and groups IId, IV and VI in Mono Mac6. Lane 1 is Mono
Mac6 cells, lane 2 is non-di¡erentiated THP-1 cells, lanes 3 and 4
are THP-1 cells di¡erentiated for 72 and 120 h, respectively, and
lane 5 is positive control.
Fig. 2. LysoPC stimulates [3H]AA and [14C]OA release in a dose-de-
pendent manner in THP-1 and Mono Mac6 cells. Prelabelled (A)
THP-1 and (B) Mono Mac6 cells were treated with 25^45 WM ly-
soPC for 10 min.
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PLA2 [28]. We show here for the ¢rst time that the group IV
cPLA2 enzyme is of importance in lysoPC-induced monocyte
AA release, due to the successful action of MAFP and the
out-ruling of partial contribution of the group VI iPLA2 by
the PAP inhibitors BEL and propranolol. This was also con-
¢rmed by the cPLA2 assay. Furthermore, evidence is also
provided for the participation of sPLA2 enzymes in lysoPC-
stimulated AA release based on concomitant AA and OA
release. As shown by Balsinde et al. [29], AA/OA release is
due to the action of secretory enzymes on the outer plasma
membrane. Whether this release is due to the action of the
group IId or V sPLA2 enzyme is uncertain because the
SB203347 inhibitor has been shown to inhibit both enzymes
[30].
There are two observations indicating that a sequential re-
lationship may exist between the secretory and cytosolic en-
zymes, (1) the AA release is totally attenuated by either an
sPLA2 inhibitor (SB203347) or a cPLA2 inhibitor (MAFP)
and (2) the cPLA2 inhibitor has equal potency on both AA
and OA release, despite the high arachidonyl selectivity of the
enzyme. Such relationships between sPLA2 and cPLA2 en-
Fig. 5. Di¡erent PLA2 inhibitors reduce lysoPC-induced [3H]AA and [14C]OA release. THP-1 cells and Mono Mac6 cells were incubated with
di¡erent inhibitors as marked in the ¢gure before treatment with lysoPC.
Fig. 6. LysoPC enhances cPLA2 activity in human-derived THP-1
cells. cPLA2 enzyme assays were done on cell lysates treated with
lysoPC or MAFP and lysoPC.
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zymes were reported by us and others earlier [20,31]. Whether
the secretory enzyme precedes the cytosolic or vice versa is
uncertain.
Cellular expression of speci¢c PLA2 enzymes depends on
cell type and state of di¡erentiation, and there is limited in-
formation on PLA2 distribution patterns in primary mono-
cytes and monocytic cell lines. Speci¢c expressions of cPLA2
enzymes include: group IV in human primary monocytes [15],
U937 [32] and THP-1 cells [33], while group VI iPLA2 is
reported from murine P388D macrophages [34]. Among the
sPLA2 enzymes constitutive expression of the group V from
the murine macrophage cell line P388D [35] and primary de-
rived monocytes [15] are reported, while expression of group
IIa sPLA2 is observed in primary, in vitro di¡erentiated
monocytes stimulated with minimally oxLDL [15]. We sys-
tematically examined the expression patterns of groups IIa,
IId, IV, V, VI and X in THP-1 and Mono Mac6 cells and
show for the ¢rst time expression of the group IId sPLA2 in
monocytes and the coexistence of groups IId, IV and VI PLA2
independently of monocyte di¡erentiation. Moreover, the
group V sPLA2 is constitutively expressed in undi¡erentiated
THP-1 cells, and we show for the ¢rst time that its expression
level diminishes upon PMA di¡erentiation and that its expres-
sion is undetectable in Mono Mac6 cells representing more
di¡erentiated monocytes compared to THP-1.
The cellular molecular mechanism of lysoPC is not com-
pletely understood, but it has been indicated that lysoPC may
elicit biological responses through the G-protein-coupled PAF
receptor [8], or on speci¢c lysoPC receptors [9,10]. Taking into
account the structure of lysoPC it is important to know if the
cellular actions of lysoPC are due to a speci¢c response or to
its amphiphatic property. Our results indicate involvement of
a Gi-protein-coupled receptor due to the inhibitory e¡ect of
PTX; however, further investigations are needed to address
the question of which receptor is involved in the response.
In summary, we have shown that lysoPC, a product of
enzymatic modi¢cation of LDL, participates in proin£amma-
tory activation of human-derived monocytes by activating
sPLA2 and cPLA2. Additionally, we observed that expression
of speci¢c PLA2 enzymes changed with di¡erentiation of
monocytes and that the proin£ammatory activation of mono-
cytes by lysoPC was partly mediated through a Gi-protein.
Our results have provided a better molecular understanding
of the speci¢c role of lysoPC in proin£ammatory monocyte
activation, and may in the future provide new potential tar-
gets for drug development.
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